atop dermat full data
later
eli lilli nr today announc baricitinib met
primari endpoint moder sever atop dermat ad could
help expand baricitinib beyond rheumatoid arthriti see note http //
full data expect later year remind
also run two phase studi mild moder ad topic ruxolitinib
weve increas pipelin valu valuat
model approach matur later line pipelin reiter
buy rate pt increas
baricitinib/olumin met primari endpoint two phase studi
help drive expans atop
dermat today eli lilli nr announc baricitinib
met primari endpoint two phase studi evalu baricitinib
monotherapi moder sever atop dermat ad primari
endpoint week defin investig global assess iga
score ad clear almost clear iga score
statist signific compar placebo incid advers event
seriou advers event similar baricitinib placebo
common treatment-emerg tr observ
nasopharyng headach venou thromboembol event vte
major advers cardiovascular event mace death report
encourag announc believ posit setup
baricitinib expans indic lilli plan share full data
later year scientif venu
well public peer-review journal today lack break-out
data mirror lilli rheumatoid arthriti ra announc comment
top-line press releas full data present medic
meetingso surpris today announc lack full
remind baricitinib current approv rheumatoid arthriti
like potenti expans ad remind baricitinib
market olumi approv last year us june
eu feb patient rheumatoid arthriti ra
olumi indic patient ra inadequ respons
one tumor necrosi factor antagonist though believ label
restrict ra patient inadequ respons neg label
also includ black box warn typic jak inhibitor believ
approv baricitinib ra demonstr benefit drug see
note remind baricitinib current on-going
tr target
phase studi indic includ two phase studi ad breeze-
see exhibit partner begin year manag highlight
baricitinib contribut meaning portion recent disclos expens exhibit
remind phase data demonstr patient moderate-to-sever ad treat
baricitinib saw improv eczema area sever index compar
control arm exhibit data present european academi dermatolog
venereolog eadv congress consequ believ like venu breeze-
may eadv possibl word congress dermatolog lilli expect
announc earn feb et expect announc earn feb
et lilli manag believ baricitinib first oral drug approv ad
us note confid baricitinib mechan action one bring innov ad
treatment fy guidanc call dec encourag lilli posit comment
baricitinib ad
exhibit baricitinib on-going phase studiesatop dermat system lupu
exhibit baricitinib contribut meaning portion late-stag develop
compani report januari
page
exhibit phase data baricitinib show signific increas respond moder
sever ad compar control respond week bari tc compar
alon
incyt franchis drug ruxolitinib also target atop dermat mild-to-moder
ad remind also develop ruxolitinib cream ad patient mild
moder ad remind two phase studi rux cream indic true-
announc first patient treat dec
may overlap rux cream baricitinib particularli patient moder ad
cream evalu patient mild-to-moder ad wherea baricitinib evalu
patient moderate-to-sever ad exhibit also remind phase data rux cream show
statist signific differ proport respond measur iga week
compar vs week vs week exhibit incyt
expect present data phase true-ad studi
exhibit competit landscap adoverlap patient moder ad rux
cream baricitinib rux cream evalu mild ad wherea baricitinib includ sever
compani report januari
page
exhibit phase data rux cream show signific increas respond mild
moder vs week vs week
compani report januari
model chang late-stag asset pemigatinib fgfr parsaclisib
start gener late-phas data approach regulatori action roll combin
pipelin valu model see varianc sheet pt increas
potenti posit catalyst feb pdufa jakafi steroid-refractori
acut gvhd data phase evalu ruxolitinib steroid-refractori agvhd
trial steroid-refractori cgvhd trial pivot data phase evalu
itacitinib treatment-nav agvhd
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt
jakafi mf pv gvhd olumi iclusig cash/
pipelin bull/bear case model yield pt risk includ failur clinic develop
competit impact jakafi olumi uptak
page
data catalyst next month highlight
page
data solid data solid tumor gitrbaricitinib phase atop data nsclc glioblastoma liver cancer c-metnovartisruxolitnib jakafi combo corticosteroidsfeb steroid-refractori acut gvhd expect data data steroid-refractori agvhd expect orr data steroid-refractori cgvhd expect orr true-ad data atop data advanc malign includ pimjakafi data file fgfr transloc file bladder data newly-diagnos acut gvhd expect orr initi treatment-nav chronic gvhd phase target clinic candid annouc incyt corpor
page
page
 jakavi mileston revenues- non-gaap adjust sale probabl success weight weight pipelin corpor
page
quarterli sale royaltiesjakafi jakafi gvhd/transplant- iclusig cml- product olumi ra us- ra row- total fair valu acquisit incom incom non-gaap inc net incom non-gaap ex incom ep product share outstand corpor
page
annual jakafi gvhd/transplant- iclusig cml- total product total fair valu acquisit incom interest incom non-gaap ex incom share outstand corpor
commercial-stag biotechnolog compani believ gener signific cash flow
two partner asset develop deep pipelin oncolog asset incyt primari commerci
asset jakafi target myelofibrosi polycythemia vera
view incyt commerci asset jakafi ruxolitinib above-p biotech growth addit
upsid new indic addit valu come olumi baricitinib non-oncolog
rheumatoid arthriti ra focus cash gener asset jakafi olumi import
driver cash flow fund deep pipelin oncolog drug view rate share buy
valuat risk
dcf/npv valuat use probabl adjust peak sale discount rate
probabl success yield pt jakafi mf pv
gvhd olumi iclusig cash/pipelin bull/bear case model
yield pt risk includ failur clinic develop competit impact jakafi
compani mention note
compani rate
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
